The results showed that the expression of these three genes (TNF-α, IL-6 and TP53) was significantly downregulated by the ASP treatment in the bone of RA-induced osteoporotic rats (Figure 9), which primarily confirmed the predicted results by network pharmacology. This evidence concerns the gene TP53 and rheumatoid arthritis.